anti-cancer cell therapy
anti-tumour T cell activity
anti-tumour immunity
Anti-tumour Therapy Tumours
tumour-mediated T cell inhibition
immune checkpoint control
immune suppression
Inhibition of T
advantageous oligonucleotides
delivery of oligonucleotides
cell Co-stimulation
pre-clinical tumour models
proper immune response
important field of cancer therapy
promising approaches
cancer vaccines
promising candidates
promising European researcher
development
surface receptor
European interests
health research
novel technique
successful project conclusion
expression of receptor genes
practical clinical application
new class of immunotherapeutics
relevant research area
German Fraunhofer society
mechanism crucial
Canadian partner McMaster University
advantages
developed drugs
significant competitive advantage
world-renowned scientific institutions
previous studies
prolific environment
good tissue bioavailability
considerable advancement
polycationic nanoparticles
key technology
career
PD-L1
PTO-antisense RNA
immunology
functionality
exon
antagonistic soluble isoforms
systemic distribution
efficacy
non-toxicity
polyethylenimine
genetics
oncology
Collaboration
employment
CTLA4
protein
antibodies
Immunotherapy
aim